Results of the Anti-T. Cruzi Activity of Ro 07-1051* IN Man

Cerisola, J. A.; Barclay, Carlos A.; Lugones, H; Ledesma, Oscar

doi:10.1007/978-1-4684-3129-2_13

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in accordance with the experience of other authors. CERISOLA et al 27 reported negative serology in 80 per cent of 76 treated children, one year after treatment. FERREIRA 30 cured seven of ten treated patients and RASSI et al 59 reported 51.6 per cent of cure rate.…”

Section: Discussionmentioning

confidence: 95%

Long term evaluation of etiological treatment of Chagas disease with benznidazole

Cançado

2002

Rev. Inst. Med. trop. S. Paulo

281

186

View full text Add to dashboard Cite

The aim of this article is to present an investigation of cure rate, after long follow up, of specific chemotherapy with benznidazole in patients with both acute and chronic Chagas disease, applying quantitative conventional serological tests as the base of the criterion of cure. Twenty one patients with the acute form and 113 with one or other of the various chronic clinical forms of the disease were evaluated, after a follow up period of 13 to 21 years, for the acute, and 6 to 18 years, for the chronic patients. The duration of the acute as well as the chronic disease, a condition which influences the results of the treatment, was determined. The therapeutic schedule was presented, with emphasis on the correlation between adverse reactions and the total dose of 18 grams, approximately, as well as taking into consideration precautions to assure the safety of the treatment. Quantitative serological reactions consisting of complement fixation, indirect immunofluorescence, indirect hemagglutination, and, occasionally, ELISA, were used. Cure was found in 76 per cent of the acute patients but only in 8 per cent of those with chronic forms of the disease. In the light of such contrasting results, fundamentals of the etiological therapy of Chagas disease were discussed, like the criterion of cure, the pathogenesis and the role of immunosuppression showing tissue parasitism in long standing chronic disease, in support of the concept that post-therapeutic consistently positive serological reactions mean the presence of the parasite in the patient's tissues. In relation to the life-cycle of T. cruzi in vertebrate host, there are still some obscure and controversial points, though there is no proof of the existence of resistant or latent forms. However, the finding over the last 15 years, that immunosuppression brings about the reappearance of acute disease in long stand chronic patients justifies a revision of the matter. Facts were quoted in favor of the treatment of chronic patients.

show abstract

Section: Discussionmentioning

confidence: 95%

Long term evaluation of etiological treatment of Chagas disease with benznidazole

Cançado

2002

Rev. Inst. Med. trop. S. Paulo

281

186

View full text Add to dashboard Cite

show abstract

“…[85][86][87][88][89][90] The use of nitroderivatives in the treatment of acute Chagas disease has had limited success. [91][92][93][94][95][96] Physicians have used these drugs sparingly because they do not eradicate T cruzi infections in 83.5% of acute cases. Further, an indirect indication of parasite persistence is provided by positive aftertreatment immunological tests.…”

Section: Chronic Chagas Diseasementioning

confidence: 99%

Chagas disease

Teixeira

Nitz

Guimaro

et al. 2006

Postgraduate Medical Journal

151

122

View full text Add to dashboard Cite

Chagas disease is the clinical condition triggered by infection with the protozoan Trypanosoma cruzi. The infection is transmitted by triatomine insects while blood feeding on a human host. Field studies predict that one third of an estimated 18 million T cruzi-infected humans in Latin America will die of Chagas disease. Acute infections are usually asymptomatic, but the ensuing chronic T cruzi infections have been associated with high ratios of morbidity and mortality: Chagas heart disease leads to unexpected death in 37.5% of patients, 58% develop heart failure and die and megacolon or megaoesophagus has been associated with death in 4.5%. The pathogenesis of Chagas disease appears to be related to a parasite-induced mutation of the vertebrate genome. Currently, treatment is unsatisfactory.

show abstract

Results of the Anti-T. Cruzi Activity of Ro 07-1051* IN Man

Cited by 2 publications

References 0 publications

Long term evaluation of etiological treatment of Chagas disease with benznidazole

Long term evaluation of etiological treatment of Chagas disease with benznidazole

Chagas disease

Contact Info

Product

Resources

About